Table 3.
Effect of CR or antioxidant supplementation on the expression of biomarkers of heart aging
| Antioxidant |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene | CR | LA | CQ | RE | CU | LY | AC | AS | TP |
| C4 | *66 | −48 | −8 | *61 | 27 | *58 | *62 | 11 | *59 |
| Csprs | *52 | 21 | −19 | *48 | *41 | *34 | *68 | *50 | *65 |
| Pah | *47 | *46 | *50 | *58 | *60 | *55 | *71 | *64 | *67 |
| Cxcl14 | *37 | −24 | 24 | *90 | *36 | *81 | *85 | 12 | *98 |
| Scap2 | *60 | 22 | *35 | *25 | *34 | *39 | *44 | *44 | *45 |
| API | 51 | 16 | 19 | 52 | 41 | 51 | 66 | 45 | 66 |
The % inhibition effect of CR or antioxidants was computed as ((O−S)/(O−Y)) × 100, where O, S, and Y are the average signal intensities of the 30-month-old control, 30-month-old CR or antioxidant-supplemented group, and 5-month-old control, respectively. API represents the average effect of the intervention on all markers tested. CR, caloric restriction; LA, α-lipoic acid; CQ, coenzyme Q10; RE, resveratrol; CU, curcumin; LY, lycopene; AC, acetyl-L-carnitine; AS, astaxanthin; TP, tempol.
*
Significantly different between S and O groups (P < 0.05).